Name Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid
Classes Immunotherapeutic Agent
Vaccine
Diseases Diphtheria
Immunological Disorder
Influenza
Tetanus
Whooping Cough

Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid

Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid is a Multivalent Vaccine. This vaccine is a combination product containing inactivated components of Diphtheria Toxoid, Tetanus Toxoid, Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate, and Hepatitis B components. The toxoids stimulate the immune system to produce antibodies against diphtheria and tetanus toxins, while the acellular pertussis component provides protection against Bordetella pertussis. The inactivated poliovirus component confers immunity against poliomyelitis, and the Haemophilus b Conjugate component protects against Haemophilus influenzae type b. The Hepatitis B component induces immunity against the hepatitis B virus.

Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid is approved for use as a 3-dose series in children from 6 weeks through 4 years of age (prior to the 5th birthday).

The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.

The adverse reactions following administration of the vaccine were-

  • irritability
  • crying
  • injection site pain
  • somnolence
  • injection site erythema
  • decreased appetite
  • fever ≥38.0°C
  • injection site swelling
  • vomiting
  • Carefully evaluate the advantages and potential drawbacks before administering Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid to individuals with a history of:
    • Fever equal to or exceeding 40.5°C (105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting for at least 3 hours within 48 hours after a previous pertussis-containing vaccine.
    • Seizures occurring within 3 days after a prior pertussis-containing vaccine.
  • In cases where Guillain-Barré syndrome manifested within 6 weeks of receiving a prior vaccine containing tetanus toxoid, there may be an elevated risk of Guillain-Barré syndrome following the administration of Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid.
  • Instances of apnea after intramuscular vaccination have been noted in certain prematurely born infants. The decision on when to administer an intramuscular vaccine, including Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid, to a prematurely born infant should be guided by an assessment of the individual infant's medical condition, considering both potential benefits and risks of vaccination.
  • Urine antigen detection may lack definitive diagnostic value in suspected H. influenzae type b disease subsequent to vaccination with Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid.

Contraindication

Serious allergic response (such as anaphylaxis) to a prior administration of Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid, any component within the vaccine, or any other vaccine containing diphtheria toxoid, tetanus toxoid, pertussis, inactivated poliovirus, hepatitis B, or Haemophilus influenzae type b.

 

Bordetella Pertussis + Diphtheria Toxoid + Haemophilus Influenzae Type B Conjugated + Hepatitis B Surface Antigen + Tetanus Toxoid is contraindicated in-

  • Encephalopathy occurring within 7 days after a previous pertussis-containing vaccine without any other discernible cause.
  • Ongoing progressive neurologic disorder until a treatment plan has been instituted and the condition has stabilized.